Revolution Medicines is a clinical-stage oncology company that develops therapies to target frontier RAS-addicted cancers. Their current projects include a selective inhibitor of SOS1, a hyperactivated selective inhibitor of mTORC1 signaling in tumors, and various RAS(ON) Inhibitors. The company has a research and development collaboration agreement with Sanofi for SHP2 inhibitors.